Core Laboratories Inc.
CLB
$12.26
-$0.36-2.85%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 236.65% | 26.88% | -60.47% | 35.69% | -67.43% |
| Total Depreciation and Amortization | -5.42% | -6.44% | -4.24% | -4.97% | -4.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -102.81% | -1,367.71% | 66.70% | -16.65% | 405.53% |
| Change in Net Operating Assets | 17.62% | 93.12% | 318.83% | 49.59% | 499.27% |
| Cash from Operations | 6.10% | 6,277.83% | 96.16% | 274.50% | 47.07% |
| Capital Expenditure | -60.12% | 21.15% | -31.83% | -38.22% | -35.38% |
| Sale of Property, Plant, and Equipment | 1,133.85% | 98.51% | -23.81% | 641.25% | -95.56% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -91.11% | 34,983.33% | -36.85% | 791.11% | -86.08% |
| Cash from Investing | -45.50% | 85.51% | -156.31% | 18.69% | -331.19% |
| Total Debt Issued | -50.00% | -79.75% | -90.80% | -41.67% | -83.33% |
| Total Debt Repaid | 25.93% | 71.08% | 75.29% | -6.25% | 67.07% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -174.89% | 10.09% | 18.59% | -4,300.00% | -12.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.43% | -0.43% | -0.43% | -0.43% | -0.65% |
| Other Financing Activities | 100.00% | 87.57% | 96.73% | 61.33% | -137.52% |
| Cash from Financing | -4.84% | -47.41% | -32,464.29% | -167.28% | -46.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.88% | 139.41% | -71.95% | -124.15% | -188.21% |